Means and Methods for Treating Angiogenesis-Related Diseases
Endostatin is an antiangiogenic protein first discovered in Folkman's laboratory at Childrens Hospital, Harvard Medical School, and Boston. The antitumor properties of this pro-tein are well established. However, the amount of protein required for injection in pa-tients was beyond production feasibility due to the poor pharmacokinetics of endostatin mon-omer.
We have shown that the problem of poor pharmacokinetics can be solved by using the Fc domain of IgG being conjugated to en-dostatin, a component of all monoclonal anti-bodies approved for patients with a number of diseases including cancer. As a result of em-ploying Fc-endostatin, the half-life in mice was increased to 2 weeks instead of 2 hours for endostatin alone, consistent with pharmacoki-netics of monoclonal antibodies
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Security vulnerability in browser interface
… allows computer access via graphics card. Researchers at Graz University of Technology were successful with three different side-channel attacks on graphics cards via the WebGPU browser interface. The attacks…
A closer look at mechanochemistry
Ferdi Schüth and his team at the Max Planck Institut für Kohlenforschung in Mülheim/Germany have been studying the phenomena of mechanochemistry for several years. But what actually happens at the…
Severe Vulnerabilities Discovered in Software to Protect Internet Routing
A research team from the National Research Center for Applied Cybersecurity ATHENE led by Prof. Dr. Haya Schulmann has uncovered 18 vulnerabilities in crucial software components of Resource Public Key…
